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Abstract
Background
In Zimbabwe, viral load (VL) testing for people living with HIV on antiretroviral therapy is per-
formed at the National Microbiology Reference Laboratory using a NucliSens machine.
Anecdotal evidence has shown that invalid graphs for “Target Not Detectable (TND)” will
upon repeat VL testing produce a valid result for virus not detected, therefore removing the
need to repeat the test. This needs formal assessment.
Objectives
To determine i) intra- and inter-rater agreement of the visual interpretation of NucliSens
graphs (Target Detectable [TD], TND and No Line [NL]) between two laboratory scientists
and ii) sensitivity, specificity and predictive values of the NucliSens graphs compared with
repeat VL results.
Method
Cross sectional study using secondary data. Two laboratory scientists independently rated
graphs one week apart for intra-rater agreement and compared final ratings with each other
for inter-rater agreement. Consensus interpretations of graphs were compared with repeat
VL results. Kappa coefficients were used to obtain measures of agreement.
Results
There were 562 patients with NucliSens graphs and repeat VL. Kappa scores were: 0.98
(Scientist A); 0.99 (Scientist B); 0.96 (Scientist A versus Scientist B); and 0.65 (NucliSens
graphs versus VL). Sensitivity, specificity, positive predictive value and negative predictive
value for graphs compared with VL were 71%, 92%, 79% and 89% respectively.
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Conclusion
Intra-and inter-rater agreements were almost perfect. The negative predictive value trans-
lates to a false negative rate of 11%. If repeat VL testing is not done, the clinical conse-
quences need to be balanced against cost savings and the risks outweigh the benefits.
Introduction
The scale up of antiretroviral therapy (ART) worldwide has been a major public health success
story, with 21.7million people accessing ART by the end of 2016[1]. Global coverage of ART
reached 59% at the end of 2017, with the largest gains made in the world’s worst affected
regions of East and Southern Africa[1]. Zimbabwe has been hard hit by the HIV/AIDS epi-
demic, but has been one of the high performing Southern African countries with respect to
care and treatment. ART was introduced in the public health sector in 2004 and since then
there has been a tremendous increase in HIV-infected patients accessing ART with numbers
exceeding 900,000 by the end of 2016[2].
In the first few years of ART scale up, the World Health Organization (WHO) recom-
mended that the response to therapy be monitored by clinical assessment and by CD4 cell
count[3]. This proved difficult in practice with many false-positive and false-negative results
for predicting ART failure[4]. In 2013, and again in 2016, WHO recommended that viral load
(VL) testing becomes the standard way to monitor the response to ART[5,6]. Testing should
be carried out at 6 months and at every 12 months thereafter to monitor treatment adherence
and whether treatment failure has occurred. This move to a viral load monitoring approach
opened up the way for the Joint United Nations Program on HIV/AIDS (UNAIDS) to release
the 90-90-90 treatment targets for HIV.7 These targets specify that by 2020, 90% of people liv-
ing with HIV will know their HIV status, 90% of people diagnosed as HIV-positive will receive
ART and 90% of those on treatment will be virally suppressed.
Zimbabwe has adopted the recent WHO Guidelines and the UNAIDS 90-90-90 targets
[6,7]. Since 2013, there has been a massive scale up of VL testing using the NucliSens platform
(Biomerieux, France) at the National Microbiology Reference Laboratory (NMRL). However,
the implementation of VL testing is not without challenges related to cost and complexity of
the testing itself. One of the key challenges is that the proportion of invalid results at the
NMRL is around 2.5%. Although this is within the acceptable range (which is 5% according to
the manufacturer), the absolute number of invalid results can be high because on average 10
000 tests are performed on the NucliSens platform per month. All invalid results are repeat
tested, and the implications for this are threefold.
First, invalid results and repeat testing often increase the laboratory turnaround time from
receipt of specimens to production of results to beyond the expected standard of 14 working
days. Second, human and material resources are expended in performing the repeat tests and
this has cost implications for the HIV/AIDS programme. Third, in some cases the remaining
plasma or Dried Blood Sample (DBS) may be insufficient for a repeat test, and the patient may
be asked to attend the health facility and submit another sample. Repeat testing for VL there-
fore comes at a cost to the programme and to the patient.
An invalid VL result is associated with three output graphs, all of which show a non-sigmoi-
dal internal control line and which are stored in the computer of the NucliSens machine.
Anecdotal evidence based on visual interpretation of the NucliSens graphs has shown that
invalid graphs with “Target Not Detectable (TND)” will upon repeat VL testing almost always
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produce a valid result for virus not detected. If this anecdotal evidence was proven in a formal
study, the laboratory could accept the visual interpretation of an invalid graph for TND as
meaning no virus detected and there would be no need to repeat the VL test, saving time,
energy and money. According to a PUBMED search, there have been no published studies on
this particular subject.
We therefore conducted this study in Zimbabwe to assess whether the visual interpretation
of invalid graphs for TND was consistently associated with no virus detected on repeat VL test-
ing. To do this, we obtained records of patients tested for VL between 2013 and 2017. We
focused our study on those that initially had invalid results which showed, “Target Detectable
(TD)”, TND or no line at all (NL) on the NucliSens graph on the initial test and were subjected
to repeat VL testing. Specific objectives were to i) document demographic and laboratory char-
acteristics of HIV patients whose records were included in the study, (ii) assess intra- and
inter-rater agreement of the visual interpretation of graphs for TD, TND and NL, and to iii)
calculate sensitivity, specificity and predictive values of visual interpretation of graphs com-
pared with repeat VL test results.
Materials and methods
Study design
This was a cross-sectional study using routinely collected secondary data.
Setting
General. Zimbabwe is a land-locked country in southern Africa with a population of
approximately 13 million and a gross domestic product (GDP) of $924 per capita, which com-
pared with $1,589 per capita for the sub-Saharan Africa region[8,9]. The country has a high
burden of HIV/AIDS with an estimated prevalence of 14.6% amongst 15–64 year old adults
[2]. Since 2004, when ART was introduced in the public health sector in Zimbabwe, the uptake
has increased in a phased and decentralized approach with close to one million people access-
ing ART country-wide from over 1500 health facilities (>90% of all health facilities in the
country)[2].
Viral load testing at national microbiology reference laboratory (NMRL). This study
was carried out at the NMRL, Harare, Zimbabwe. The NMRL has conducted all VL testing for
the country up to February 2017, at which point VL testing was decentralized to different prov-
inces. All VL testing in NMRL was done using the NucliSens platform (Biomerieux, France)
up to February 2017 when Abbott M2000sp and M2000rt machines (Abbott Laboratories, Illi-
nois, USA) were also procured for the laboratory. The majority of samples sent from ART sites
from around the country are dried blood spots (DBS) with five spots on each card. The only
exception is Harare Central Hospital which sends plasma for VL rather than DBS. This is
because the NMRL is located within Harare Central Hospital Complex. The procedures for
collecting DBS samples and VL testing are described in the NMRL handbook and standard
operating procedures manual[10,11]. The NMRL participated in External Quality Assessment
with the Centres for Disease Control and Prevention Global AIDS Program(CDC GAP),
receiving 100% accuracy for each of the cycles in which it participated from 2013 to 2017.
Once the VL test has been completed, the machine provides a graphic representation and a
printed results summary. Both of these are stored within the machine’s computer system. The
printed results summary gives one of the following results: i) invalid result, ii) target virus not
detected, or iii) target virus detected with a numeric count of the viral load in copies per ml. As
described earlier, all invalid VL results are repeat tested using the remaining samples on the
DBS or plasma card.
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Interpretation of the VL output graphs from the NucliSens machine. The NucliSens
machine produces one of five output graphs: two are valid graphs and three are invalid graphs
as shown in Figures A-E in S1 Fig.
For a valid graph, the screen always shows a sigmoid line for the internal control. For the
tested specimen, any visible graph line means virus is detected (TD) (Fig A in S1 Fig) and no
graph line means no virus is detected (TND) (Fig B in S1 Fig).
For an invalid graph, the screen shows no line(NL) at all for the internal control (which
indicates no amplification) (Fig C in S1 Fig), non-sigmoidal lines for both the internal control
and tested specimen (which indicates incomplete amplification) (Fig D in S1 Fig) or a non-sig-
moidal line for the internal control (which indicates incomplete amplification for internal con-
trol only) (Fig E in S1 Fig): in these circumstances the summary print out gives “Invalid
Result”. For the patient’s tested specimen, any visible graph line means virus is detected (TD)
and no graph line means no virus is detected (TND).
Study population. HIV-infected people on ART who had an initial invalid NucliSens
graph and a repeat VL test in Zimbabwe between 2013 and 2017 were included in the study.
Study procedure, intra- and inter-rater variability and comparisons with repeat VL. A
line list was made of all the initial invalid VL results that had a repeat VL test. From these, the
principal investigator made a list of patients who had graphs (TD, TND and NL). For every
TND graph, controls were selected that either had a TD or an NL graph. The graphs were then
mixed up. Two similarly experienced medical laboratory scientists (A and B) were trained to
interpret the graphs for TND, TD or NL.
Intra-rater agreement: each scientist independently decided on whether the graphs were
TD, TND or NL at time T1. The same scientist looked again at the graphs one week later,
blinded to what they had decided previously, and decided whether the graphs were TD, TND
or NL (T2). The results from T1 and T2 were compared for intra-rater agreement.
Inter-rater agreement: the final decisions on graphs were obtained for each scientist and
these were compared between the two to enable inter-rater agreement to be assessed. Each sci-
entist’s final decision was based on whether they agreed on each graph between T1 and T2 –if
they had not agreed, they were asked to look for a third time at the graph and make a decision
which was accepted as the final decision.
Comparison of graphs with the result of repeat VL testing: When there had been disagreement
between the two scientists, a consensus was reached between them on whether the graph was
either TD or TND. The concordant results of the two scientists were then compared with the
repeat VL printed results–virus detected or virus not detected. The data appears in S1 Dataset.
Data variables. Data variables for the study were collected into a structured proforma and
included: sex; age; reason for viral load testing; graphs selected by the principal investigator as
showing TD, TND and NL; repeat VL printed results that showed virus detected and virus not
detected. The data codebook appears in “S2 Dataset. Code book”. The data source was the
computer system of the NucliSens platform and VL laboratory electronic information system.
Analysis and statistics. Data were double entered from the paper-based form into Epi-
Data (version 4.0.1.44 for data entry and version 2.2.2.186 for data analysis (EpiData Associa-
tion, Odense, Denmark). These data were exported to STATA (version 13, StataCorp LP,
Texas, US).The kappa coefficient (with 95% confidence intervals [CI]) of agreement and its
interpretation was used to determine intra- and inter-rater agreement on the visual interpreta-
tion of NucliSens graphs (TD, TND and NL) by the two scientists (A and B)[12]. A two-by-
two table was constructed to compare the visual interpretation of the graphs (TD and TND)
with the repeat VL test result, and this was used to calculate sensitivity, specificity and predic-
tive values.
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Ethics. Ethics approval was obtained from the Medical Research Council of Zimbabwe
and the Ethics Advisory Group, International Union Against Tuberculosis and Lung Disease
(The Union) Paris, France. As secondary data were used, a waiver for informed patient con-
sent was obtained from the ethics committees.
Results
There were 562 patients whose characteristics are shown in Table A in S1 Tables. The majority
of patients were aged 18 years or above and in those where gender was recorded the majority
was female. All the patients were on ART and had submitted specimens for VL testing as part
of follow-up and monitoring. Just over half of the patients had a graph that showed TND, with
the remainder divided between TD (17%) and NL (32%). Repeat VL results for the study were
only retrieved from the 384 patients who had a graph showing TD and TND.
Intra-rater agreement between scientist A and scientist B in the visual interpretation of
invalid NucliSens graphs for TD, TND and NL are shown in Table B in S1 Tables. There was
almost perfect agreement, with scientist A having a kappa score of 0.98 between the two read-
ings one week apart and scientist B having a kappa score of 0.99.
Inter-rater agreement between Scientist A and B in the visual interpretation of invalid
NucliSens graphs for TD, TND and NL are shown in Table C in S1 Tables. There was an
almost perfect agreement with a kappa score of 0.96.
Agreement in the visual interpretation of the NucliSens graphs showing TD and TND and
the repeat viral load results showing virus detected and virus not detected are shown in
Table D in S1 Tables. There was a substantial agreement with a kappa score of 0.65. Sensitivity,
specificity, positive predictive value and negative predictive value for visual interpretation of
graphs compared with repeat viral load test results were 71%, 92%, 79% and 89% respectively.
Discussion
This study confirms that based on the kappa score there was substantial agreement between
visual interpretation of the NucliSens graphs showing TND and repeat viral load test results
showing virus not detectable. Visual interpretation of the graphs was also straight forward and
replicable as indicated by the almost perfect intra-rater and inter-rater agreements when two
trained medical laboratory scientists conducted this exercise independently one week apart.
From the point of view of laboratory policy, the key question that needed to be asked was
whether the visual interpretation of invalid graphs for TND was consistently associated with
no virus detectable and could the laboratory therefore dispense with repeat viral load testing.
The high specificity in our study means that 92% of patients with no virus detectable had an
invalid graph showing TND. The high negative predictive value means that 89% of invalid
graphs showing TND had no virus detectable on repeat VL testing. However, this translates to
a false negative rate of 11%; namely that when a medical laboratory scientist concludes that the
NucliSens graph of an invalid test shows TND there is in fact detectable virus in the specimen.
Does a false negative rate of 11% matter in terms of laboratory, clinical and programmatic
management? In clinical practice, it would mean that 11% of patients on ART would be
assessed as having viral suppression when this is not the case and virus is indeed present. The
most recent WHO guidelines specify that if virus is present in a patient sample, then a precise
VL must be obtained[6]. If the VL is>1000 copies per mL, then adherence counselling has to
be done and the patient reassessed three months later with a repeat VL test. If the repeat VL is
still high, the patient is judged to have failed the ART regimen which he/she is taking, there
might be further tests conducted for HIV drug resistance and the patient would be started on
another more suitable ART regimen[6]. If the repeat VL test was not done, none of this clinical
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and laboratory management would take place and the patient would have to wait for another
12 months until the next repeat VL test is scheduled.
Is it safe to leave a patient on ART with detectable virus for another 12 months before the
next repeat VL monitoring test? Probably not! It is well established that detectable virus leads
to immunosuppression which increases the risks of further morbidity and mortality. ART
with viral suppression effectively prevents the transmission of HIV to other non-infected per-
sons[13,14], and conversely the presence of detectable virus increases the risk of HIV transmis-
sion[15]. Thus, detectable virus means that there is a risk that the patient deteriorates clinically
as well as transmits HIV to his/ her non-infected partner. HIV drug resistance also needs to be
considered, especially for patients already on ART, and unfortunately, HIV drug resistance is a
growing threat globally to epidemic control[16]. This is particularly the case in sub-Saharan
Africa, where pretreatment resistance to non-nucleoside reverse transcriptase inhibitors in
2016 was greater than 10% in southern and eastern African countries[17]. Detectable virus
after the patient has been on ART for some time means there is a risk for drug resistance, and
if this is not diagnosed and managed there is further risk of resistance amplification. Thus, the
option of leaving clinical staff and patients to believe that virus is suppressed based on visual
interpretation of the NucliSens graph, when this is not the case, is not good clinical or pro-
grammatic management.
What are the cost savings of this potential approach of accepting invalid TND NucliSens
graphs as indicating no virus detected and therefore not repeating the VL test? Working on
10,000 VL tests per month (the approximate workload of the NMRL) with 2.5% being invalid,
there would be 250 invalid tests of which half (125) would be TND. Each VL test costs about
USD$80 and with none of these TND tests being repeated, there would be a cost savings of
USD$10,000 per month or USD$120,000 per annum. For a resource-poor country such as
Zimbabwe, this is a considerable cost saving for the NMRL.
The main strengths of the study were the large sample size, the NMRL being the major ref-
erence laboratory for the whole country and the rigorous methodology for ascertaining intra-
and inter-rater agreements and sensitivity, specificity and predictive values. The NMRL also
participates in an external quality assurance programme with excellent results, and therefore
the results of VL testing are probably accurate and consistently reproducible. The main limita-
tions were a failure to collect more detailed baseline clinical information on the patients which
may have been useful for further analysis and we did not collect precise measurements of VL
in copies/mL which would have helped in deciding who had VL above and below 1000 copies/
mL on the 11%.
We are unaware of any previous published studies on this subject and therefore cannot
compare our findings with those of others. The way forward is for us now to present this data
and information to programmatic, clinical and laboratory stakeholders, including those who
are responsible for policy decisions within the National AIDS Programme, and decide on what
further studies should be done to clarify the situation (such as measuring VL in copies/mL)
and on whether or not to dispense with repeat VL testing in those patients for whom an invalid
NucliSens graph shows TND. Although there may be considerable cost savings from this
approach, there are clinical and programmatic risks, and we feel that we cannot recommend a
policy of not repeating the VL if an invalid initial test shows a TND graph.
In conclusion, we evaluated whether the visual interpretation of invalid graphs for TND
were consistently associated with no virus detected on repeat VL testing. While we observed
excellent intra- and inter-agreement between the two trained medical laboratory scientists in
visual interpretation of the graphs, the specificity and negative predictive values of TD and
TND graphs against repeat VL test results were 92% and 89% respectively. The false negative
rate of 11% with its programmatic and clinical consequences has to be balanced against the
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cost savings of dispensing with the repeat VL test. On balance the risks outweigh the benefits
and we cannot recommend a policy of no repeat VL testing.
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